Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Almonertinib Alone Versus Almonertinib Plus Chemotherapy as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive With Concomitant Non-EGFR Driver Gene Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Multicenter, Open-label, Randomized, Control Phase III Study (ACROSS 1)

NCT04500704 is registered in ClinicalTrials.gov with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT04500704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04500704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Almonertinib Alone Versus Almonertinib Plus Chemotherapy as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive With Concomitant Non-EGFR Driver Gene Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Multicenter, Open-label, Randomized, Control Phase III Study (ACROSS 1)
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase
Phase 3
Overall status
Unknown status
Start date
October 31, 2020
Completion date
October 31, 2023
Enrollment
166 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer